

Endovascular Thrombectomy for Acute Ischemic Stroke Beyond 6 Hours From Onset: A Real-World Experience

Ilaria Casetta 1, Enrico Fainardi 2, Valentina Saia 3, Giovanni Pracucci 4, Marina Padroni 1, Leonardo Renieri 5, Patrizia Nencini 4, Domenico Inzitari 4, Daniele Morosetti 6, Fabrizio Sallustio 7, Stefano Vallone 8, Guido Bigliardi 9, Andrea Zini 10, Marcello Longo 11, Isabella Francalanza 12, Sandra Bracco 13, Ignazio M Vallone 13, Rossana Tassi 14, Mauro Bergui 15, Andrea Naldi 16, Andrea Saletti 17, Alessandro De Vito 18, Roberto Gasparotti 19, Mauro Magoni, Lucio Castellani 20, Carlo Serrati 21, Roberto Menozzi 22, Umberto Scoditti 23, Francesco Causin 24, Alessio Pieroni 25, Edoardo Puglielli 26, Alfonsina Casalena 27, Antioco Sanna 28, Maria Ruggiero 28, Francesco Cordici 29, Luca Di Maggio 30, Enrica Duc 31, Mirco Cosottini 32, Nicola Giannini 33, Giuseppina Sanfilippo 34, Federico Zappoli 34, Anna Cavallini, Nicola Cavasin 35, Adriana Critelli 36, Elisa Ciceri 37, Mauro Plebani 37, Manuel Cappellari 38, Luigi Chiumarulo 39, Marco Petruzzellis 40, Alberto Terrana 41, Lucia Princiotta Cariddi 42, Nicola Burdi 43, Angelica Tinelli 44, William Auteri 45, Umberto Silvagni 45, Francesco Biraschi 46, Ettore Nicolini 47, Riccardo Padolecchia 48, Tiziana Tassinari 49, Pietro Filauri 50, Simona Sacco 51, Marco Pavia 52, Paolo Invernizzi 53, Nunzio P Nuzzi 54, Simona Marcheselli 55, Pietro Amistà 56, Monia Russo 57, Ivan Gallesio 58, Giuseppe Craparo 59, Marina Mannino 60, Salvatore Mangiafico 5, Danilo Toni 47; Italian Registry of Endovascular Treatment in Acute Stroke

1Clinica Neurologica, University of Ferrara, (I.C., M.P.).

2Neuroradiology Unit, University of Florence (E.F.).

3Stroke Unit, Santa Corona Hospital, Pietra Ligure (V.S.).

4Stroke Unit, Careggi University Hospital, Florence (G.P., P.N., D.I.).

5Interventional Neuroradiology Unit, Careggi University Hospital, Florence (L.R., S.M.).

6Diagnostic Imaging and Interventional Radiology Unit (D.M.), University of Rome Tor Vergata.

7Stroke Unit (F.S.), University of Rome Tor Vergata.

8Interventional Neuroradiology Unit (S.V.), Ospedale Civile "S.Agostino-Estense", AOU Modena.

9Stroke Unit (G.B.), Ospedale Civile "S.Agostino-Estense", AOU Modena.

10Neurology and Stroke Unit, Maggiore Hospital, Bologna (A.Z.).

11Interventional Neuroradiology Unit, Policlinico G Martino, Messina (M.L.).

- 12Stroke Unit, Policlinico G. Martino, Messina (F.I.).
- 13Neuroimaging and Neurointervention Unit (NINT), AOU Senese, Siena (S.B., I.M.V.).
- 14Stroke Unit, University Hospital "S. Maria delle Scotte", Siena (R.T.).
- 15Interventional Neuroradiology Unit, Città della Salute e della Scienza-Molinette, Turin (M.B.).
- 16Department of Neuroscience "Rita Levi Montalcini", University of Turin (A.N.).
- 17Interventional Neuroradiology Unit, University Hospital "Arcispedale S. Anna", Ferrara (A.S.).
- 18Stroke Unit, University Hospital "Arcispedale S. Anna", Ferrara (A.D.V.).
- 19Interventional Neuroradiology Unit, "Spedali Civili", Brescia (R.G.).
- 20Interventional Neuroradiology Unit, IRCCS San Martino-IST, Genova (L.C.).
- 21Neurology and Stroke Unit, IRCCS San Martino-IST, Genova (C.S.).
- 22Interventional Neuroradiology Unit (R.M.), University Hospital, Parma.
- 23Stroke Unit (U.S.), University Hospital, Parma.
- 24Neuroradiology Unit (F.C.), Padua University Hospital.
- 25Stroke Unit and Neurosonology Lab (A.P.), Padua University Hospital.
- 26Vascular and Interventional Radiology Unit (E.P.), Ospedale Civile "Mazzini", Teramo.
- 27Neurology Unit (A.C.), Ospedale Civile "Mazzini", Teramo.
- 28Neuroradiology Unit (A.S., M.R.), "M. Bufalini" Hospital-AUSL Romagna, Cesena.
- 29Neurology Unit (F.C.). "M. Bufalini" Hospital-AUSL Romagna, Cesena.
- 30Interventional Radiology and Neuroradiology Unit (L.D.M), San Giovanni Bosco Hospital, Torino.
- 31Neurology Unit (E.D.), San Giovanni Bosco Hospital, Torino.
- 32Neuroradiology Unit (M.C.), AOU Pisa.
- 33Neurology Unit (G.N.), AOU Pisa.
- 34Radiology, Diagnostic and Interventional Neuroradiology Unit, Policlinico IRCCS San Matteo, Pavia (G.S., F.Z.).
- 35Neuroradiology Unit (N.C.), Ospedale dell'Angelo-USSL3 Serenissima, Mestre.
- 36Neurology Unit (A.C.), Ospedale dell'Angelo-USSL3 Serenissima, Mestre.
- 37Neuroradiology Unit (E.C., M.P.), AOUI Verona.
- 38Neurology Unit (M.C.), AOUI Verona.
- 39Interventional Neuroradiology Unit (L.C.), Policlinico Bari.

- 40Stroke Unit (M.P.), Policlinico Bari.
- 41Neuroradiology Unit (A.T.), AOU Circolo, ASST-Settelaghi, Varese.
- 42Neurology and Stroke Unit (L.P.C.), AOU Circolo, ASST-Settelaghi, Varese.
- 43Interventional Radiology (N.B.), Ospedale SS. Annunziata, Taranto.
- 44Stroke Unit (A.T.), Ospedale SS. Annunziata, Taranto.
- 45Interventional Neuroradiology Unit, AO Annunziata, Cosenza (W.A., U.S.).
- 46Interventional Neuroradiology Unit, Policlinico Umberto I, Rome (F.B.).
- 47Emergency Department Stroke Unit, Sapienza University Hospital, Rome (E.N., D.T.).
- 48Neuroradiology Unit (R.P.), S. Corona Hospital-ASL2 Savonese, Pietra Ligure.
- 49Neurology and Stroke Unit (T.T.), S. Corona Hospital-ASL2 Savonese, Pietra Ligure.
- 50Interventional Neuroradiology Unit, PO SS. Filippo e Nicola, Avezzano (P.F.).
- 51Department of Applied Clinical Sciences e Biotechnology, University of L'Aquila, L'Aquila (S.S.).
- 52Neuroradiology Unit (M.P.), Istituto Ospedaliero Fondazione Poliambulanza, Brescia.
- 53Neurology Unit (P.I.), Istituto Ospedaliero Fondazione Poliambulanza, Brescia.
- 54Interventional Neuroradiology Unit (N.P.N.), Humanitas Research Hospital, Rozzano.
- 55Urgent Neurology and Stroke Unit (S.M.), Humanitas Research Hospital, Rozzano.
- 56Interventional Neuroradiology Unit (P.A.), S. Maria della Misericordia Hospital, Rovigo.
- 57Stroke Unit (M.R.), S. Maria della Misericordia Hospital, Rovigo.
- 58Neuroradiology Unit, SS. Antonio e Biagio e C. Arrigo Hospital, Alessandria (I.G.).
- 59Interventional Neuroradiology Unit (G.C.), Ospedale Civico-A.R.N.A.S., Palermo.
- 60Stroke Unit (M.M.), Ospedale Civico-A.R.N.A.S., Palermo.

Abstract

Background and Purpose:

To evaluate outcome and safety of endovascular treatment beyond 6 hours of onset of ischemic stroke due to large vessel occlusion in the anterior circulation, in routine clinical practice.

Methods:

From the Italian Registry of Endovascular Thrombectomy, we extracted clinical and outcome data of patients treated for stroke of known onset beyond 6 hours. Additional inclusion criteria were prestroke modified Rankin Scale score ≤ 2 and ASPECTS score ≥ 6 . Patients were selected on individual basis by a combination of CT perfusion mismatch (difference between total hypoperfusion and infarct core sizes) and CT collateral score. The primary outcome measure was the score on modified Rankin Scale at 90 days. Safety outcomes were 90-day mortality and the occurrence of symptomatic intracranial hemorrhage. Data were compared with those from patients treated within 6 hours.

Results:

Out of 3057 patients, 327 were treated beyond 6 hours. Their mean age was 66.8 ± 14.9 years, the median baseline National Institutes of Health Stroke Scale 16, and the median onset to groin puncture time 430 minutes. The most frequent site of occlusion was middle cerebral artery (45.1%). Functional independence (90-day modified Rankin Scale score, 0–2) was achieved by 41.3% of cases. Symptomatic intracranial hemorrhage occurred in 6.7% of patients, and 3-month case fatality rate was 17.1%. The probability of surviving with modified Rankin Scale score, 0–2 (odds ratio, 0.58 [95% CI, 0.43–0.77]) was significantly lower in patients treated beyond 6 hours as compared with patients treated earlier. No differences were found regarding recanalization rates and safety outcomes between patients treated within and beyond 6 hours. There were no differences in outcome between people treated 6–12 hours from onset (278 patients) and those treated 12 to 24 hours from onset (49 patients).

Conclusions:

This real-world study suggests that in patients with large vessel occlusion selected on the basis of CT perfusion and collateral circulation assessment, endovascular treatment beyond 6 hours is feasible and safe with no increase in symptomatic intracranial hemorrhage.

Introduction

Randomized controlled trials (RCTs) on acute ischemic stroke (AIS) due to large vessel occlusion (LVO) established the superiority of endovascular thrombectomy (EVT) in addition to the best medical management, including intravenous thrombolysis, over best medical management alone within 6 hours from symptom onset.^{1–6} Some of these trials enrolled patients up to 85 or 12 hours² from symptom onset. The HERMES collaboration individual patient data meta-analyses^{7,8} of the first 5 RCTs^{1–5} showed that the probability of functional independence (modified Rankin Scale [mRS], 0–2) at 3 months was 46.1%,⁷ and that although the magnitude of benefit declines as time from symptom onset to groin puncture increases, the treatment benefit also remains beyond 6 hours after stroke onset, but it becomes nonsignificant after 7.3 hours.⁸

More recent trials demonstrated that the time window for endovascular treatment can be extended up to 169 or 24 hours¹⁰ from the last time the patient was known to be well, when the selection is based on neuroimaging evaluation showing a salvageable penumbra⁹ or a mismatch between clinical deficit and infarct size.¹⁰ As a result, current guidelines^{11,12} recommend thrombectomy in the 6- to 24-hour time window for patients meeting the DAWN¹⁰ and DEFUSE-3 trial⁹ criteria. The DAWN and DEFUSE-3 trials^{9,10} focused on

patients who suffered mainly from unwitnessed or wake-up stroke. Only 10% of treated patients and 14% of control patients in the DAWN study¹⁰ and 34% and 39% of patients and controls, respectively, in the DEFUSE-3 trial⁹ were treated beyond 6 hours after witnessed stroke onset.

The aim of this study is to evaluate the outcome and safety of EVT in patients with anterior circulation AIS due to a proximal intracranial artery occlusion who were treated beyond 6 hours from known symptom onset in a large real-world cohort of patients included in the Italian Registry of Endovascular Thrombectomy.

Methods

The source of data is the Italian Registry of Endovascular Stroke Treatments, a multicenter, prospective, observational internet-based registry which includes patients treated with thrombectomy since 2011. The purposes, organization, and structure of the Registry were previously described in more detail.^{13,14} This registry was implemented to collect baseline and outcome information for all treated patients and to share experiences and operational protocols, with the aim to improve and standardize quality of care delivered throughout the national territory. Centers included in the registry were required to accept the rules of the registry, including consecutive registration of all patients with stroke receiving endovascular procedures, participation in regular meetings, and incorporation of the proposed operational protocols in their routine local practice. The data that support the findings of this study are available from the corresponding author upon reasonable request. Ethical approval from the ethics committees of the participating centers and patient informed consent were obtained. According to national guidelines,¹⁵ patients admitted within 6 hours of stroke onset were considered eligible for endovascular treatment if the following inclusion criteria were fulfilled: LVO documented on CT angiography (CTA), a baseline CT Alberta Stroke Program Early CT Score (ASPECTS) ≥ 6 , and a prestroke mRS score ≤ 2 . However, in selected patients, endovascular procedure was conducted beyond 6 hours after stroke onset. The decision to treat beyond the standard therapeutic window was individualized on the basis of findings obtained from admission brain noncontrast CT scans, CTA of cervical vessels, head single-phase CTA or preferably, multi-phase CTA of intracranial vessels and CT perfusion (CTP). The extension of early ischemic changes was evaluated on noncontrast CT by using ASPECTS. Collateral supply was graded on a 4-point scale for single-phase CTA,¹⁶ in which collaterals were categorized as poor (scores, 0–1) and good (scores, 2–3), and on a 6-point scale for multi-phase CTA, in which collaterals were classified as poor (grade, 0–3) and good (scores, 4–5).¹⁷ Cerebral blood flow, cerebral blood volume, and mean-transit-time CTP maps were generated for each patient. CTP was evaluated according to the classical CTP mismatch model¹⁸: (1) mean-transit-time lesion indicating total hypoperfusion; (2) cerebral blood volume lesion referring to infarct core; and (3) mean-transit-time-cerebral blood volume representing ischemic penumbra. CTP mismatch was defined as the difference between total hypoperfusion and infarct core size and was evaluated by visual inspection. For each modality, patients were judged to be candidates for EVT based on the following criteria: (1) noncontrast CT ASPECTS ≥ 6 ; (2) good collateral circulation (single-phase CTA collateral score of 2–3 or multi-phase CTA collateral score of 4–5); (3) CTP mismatch with an infarct core size $\leq 50\%$ of total hypoperfusion extent or involving less than one-third of the MCA territory extent

according to Turk et al¹⁹ and to mismatch ratio model. Patients with noncontrast CT ASPECTS <6, with poor collaterals, without CTP mismatch or with CTP mismatch but an infarct core size >50% of total hypoperfusion extent or involving more than one-third of the MCA territory extent, with an inability to complete multimodal CT protocol at baseline or with poor CT quality were excluded. The same inclusion and exclusion criteria were also used for the selection of patients treated with endovascular therapy within 6 hours of stroke onset. We extracted data for patients with LVO (occlusion of the internal carotid artery, and middle cerebral artery M1 or M2), treated within and beyond 6 hours of stroke onset between 2011 and 2017. Patients with an occlusion of middle cerebral artery M3, anterior cerebral artery, or the posterior circulation were excluded. To include only cases definitely treated beyond 6 hours, patients with unknown onset of stroke (due to patients being unconscious, disoriented or aphasic, when a witness was not available, or when the patient awoke with stroke symptoms) were excluded from this analysis. For each patient, demographics, stroke risk factors, prestroke mRS, stroke severity (National Institutes of Health Stroke Scale [NIHSS] at admission), baseline neuroimaging, and data on endovascular treatment were collected. Clinical follow-up was assessed by mRS at 3 months. The primary outcome measure was the score on mRS at 90 days, as assessed by a local trained neurologist through in-person visit, or through a phone standardized interview when a face-to-face assessment was not possible. We examined the following dichotomizations of the mRS score: 0 to 1 versus 2 to 6, 0 to 2 versus 3 to 6, and 0 to 3 versus 4 to 6. For efficacy measures, arterial recanalization was rated according to the Thrombolysis in Cerebral Infarction (TICI) score.²⁰ Successful recanalization was defined as TICI score 2b or 3, while TICI 3 defined as complete recanalization. Symptomatic intracranial hemorrhage (sICH) was defined as any intracranial hemorrhage associated with a 4 point increase in the 24 hours NIHSS score, according to the ECASS II definition.²¹ sICH, procedural adverse events (subarachnoid hemorrhage and vessel dissection), and death rate were considered safety measures.

Statistical Analysis

Data were presented as absolute numbers, percentages, mean±SD if normally distributed or median and interquartile ranges, as appropriate. Dichotomous variables were compared using the χ^2 test, while continuous variables were compared by Student t test or Mann-Whitney U test as appropriate on the basis of data distribution. A multivariable logistic regression analysis to adjust for sex, age, history of hypertension, diabetes mellitus, dyslipidemia, atrial fibrillation, smoking status (current or former), NIHSS score at entry, site of occlusion, and ASPECTS score, was also run to compare outcome and safety measures between subgroups of patients treated at different times. The functional outcome was further evaluated with ordinal logistic regression, taking the whole range of mRS into account as a dependent variable adjusted for the above variables. The adjusted common odds ratio (OR) and corresponding 95% CI for a shift in the direction of a better outcome on the modified Rankin scale was, therefore, calculated. A $P < 0.05$ was considered significant for all tests.

Results

Out of 3057 patients with AIS whose time at stroke onset was known, 327 (164 women and 163 men) treated beyond 6 hours after symptom onset were included in the analysis. Their mean age was 66.8±14.9 years. Good collaterals were identified by single-phase CTA in 209

and by multi-phase CTA in 118 patients. All patients had a CTP mismatch. Of these, infarct core size was considered $\leq 50\%$ of total hypoperfusion extent in 174 and less than one-third the middle cerebral artery territory extent in 153 patients. Table 1 summarizes clinical and demographic data of included patients. The median NIHSS score at baseline was 16 (interquartile range, 12–20). The most frequent site of occlusion was the middle cerebral artery M1 (45%). The median onset-to-groin puncture time was 430 minutes (interquartile range, 390–570). Two hundred and one patients (61.5%) were treated between 361 and 480 minutes, 55 (16.8%) between 481 and 600 minutes, 22 patients (6.7%) between 601 and 720 minutes, and 49 patients (15%) beyond 12 hours (up to 24 hours) from symptoms onset. Functional independence (mRS, 0–2) at 90-day follow-up was achieved by 41.3% of cases (Table 2). The proportion of patients with stroke with complete recovery or minimal disability at 3 months (mRS, 0–1) was 26.9%, while 53.2% of patients survived with a disability range of 0 to 3. The 3-month case fatality rate was 17.1%. sICH occurred in 22 patients (6.7%). A successful recanalization was achieved in 232 patients (70.9%), while TIC1 score of 3 was recorded in 167 subjects (51.1%).

When focusing on patients with internal carotid artery and M1 occlusion (excluding those with M2 occlusion), the findings concerning outcomes were not significantly different, since the proportions of patients with 90-day mRS 0 to 1, 0 to 2, and 0 to 3 were 25.4% (72/284), 39.1% (111/284), and 50.4% (143/284), respectively. Twenty-one patients (7.4%) had sICH, and the 3-month case fatality was 17.3% (49/284). Complete recanalization was achieved in 146 (51.4%) of patients, and TIC1 2b/3 was recorded in 200 (70.4%).

We compared outcome data between patients who underwent EVT beyond 6 hours and patients with AIS treated within 6 hours of symptom onset extracted by the Italian Registry with the same selection criteria (Table 1). This population included 2730 patients (1352 men and 1378 women) with a mean age of 69.73 ± 13.6 SD and a median NIHSS at baseline of 18 (interquartile range, 13–21).

Patients treated beyond 6 hours were significantly younger than patients treated earlier ($P < 0.001$), had a lower baseline NIHSS score ($P < 0.01$), and a lower median ASPECTS score. No significant differences were found regarding vascular risk factors and comorbidities. A tandem occlusion was more frequent in patients treated later ($P < 0.01$).

The comparison of outcomes in patients treated beyond and within 6 hours was reported in Table 2. The common adjusted OR for a shift toward a better outcome was 1.59 (1.27–2.02) in favor of patients treated earlier.

The multivariable logistic regression analysis showed that the probability of surviving with mRS 0 to 1 (OR, 0.52 [95% CI, 0.38–0.7]), mRS 0 to 2 (OR, 0.58 [95% CI, 0.43–0.77]), or mRS 0 to 3 (OR, 0.59 [95% CI, 0.44–0.78]) was significantly lower in patients treated beyond 6 hours. No differences were found regarding recanalization rates and safety outcomes.

We compared baseline characteristics and outcomes (Table 4) of patients treated between 6 and 12 hours and those treated beyond 12 hours. We found no significant differences

between these 2 groups, except for a higher probability for survival with mRS 0 to 3 in the group of patients treated 6 to 12 hours after stroke onset.

Discussion

In this study, we analyzed outcome and safety data for patients with AIS treated with EVT beyond 6 hours from witnessed symptom onset in a real-world setting. EVT eligibility was decided by a combination of collateral score and CTP mismatch assessed by visual inspection. A qualitative evaluation of CTP mismatch was used due to the limited availability of automated software programs for a threshold-based calculation of infarct core, ischemic penumbra volumes, and of mismatch ratio (target mismatch) at the time of patient enrollment in Italy. We adopted an integrated approach, including CTA collateral score and CTP mismatch; this approach has recently been demonstrated to be promising for the selection of patient with AIS candidates for reperfusion therapies.^{22,23}

Mortality and sICH of patients treated beyond and within the conventional time window were not significantly different, suggesting that patient with AIS treated later from onset, selected for EVT using the eligibility criteria described above, had safety profiles comparable to patient with AIS treated earlier.

Patients who underwent EVT beyond 6 hours (within 24 hours) from symptom onset had a 27% probability to survive with no or very mild disability and a 41.3% probability of functional independence at 3 months after stroke. These results are similar to those reported from a meta-analysis on individual patients data⁸ from 5 RCT trials^{1–5} that identified 147 patients with stroke due to LVO of the anterior circulation treated beyond 6 hours either with mechanical thrombectomy (n=77) or with standard medical care (n=70); the proportion of patients surviving with functional independence (mRS, 0–2) was 39% for patients who underwent endovascular treatment and 24.4% in the control (best medical therapy) group. Our findings were also consistent with data from previous observational studies testing the possibility to extend the time window for EVT beyond 6 hours by using advanced brain imaging, including CTP and magnetic resonance diffusion-weighted imaging (MR-DWI) and perfusion-weighted imaging (MR-PWI).^{17,24–33} CTP, MR-DWI, and MR-PWI selection criteria were established by visual inspection in all but one²³ of these articles. In one study, advanced imaging was adopted in 34% of patients.³³ In these studies, the number of included patients ranged from 2125 to 2682; the site of occlusion involved anterior circulation^{25,26,28–33} and either anterior or posterior circulation;^{17,24,27,28} patients were treated beyond 8 hours,^{24,26,29,30} beyond 7 hours,¹⁷ beyond 6 hours from symptom onset, or, more frequently, from time last seen well^{25,27,28,31–33}; the proportion of patients achieving a good functional outcome (90-day mRS, 0–2) ranged from 32%³¹ to 62%,³³ and the case fatality rate ranged from 13% to 26.2% (Table 5). The utility of advanced imaging in the selection of late-presenting patients with AIS with LVO was further confirmed by a recent single-center study showing a good outcome in 36% of patients when those with baseline mRS >2 were excluded.³⁴

In our study, the comparison between patients treated within and beyond 6 hours after symptom onset demonstrated that the chance of good clinical outcome declined with longer onset to treatment intervals, without significantly affecting safety outcomes. Recent late window trials^{9,10} showed a favorable outcome rate of 49% and 45%, respectively, similar to that reported by the HERMES Collaboration meta-analysis of early window trials.⁷ However, it should be acknowledged that the HERMES study incorporated early window patients selected with CT and CTA without further advanced imaging, leading to the potential inclusion of a proportion of patients with a matched core and penumbra: this could have blunted the differences in outcome between patients treated in the early and late time windows. In fact, in RCTs enrolling patients in early time windows with advanced imaging (EXTEND IA and SWIFT PRIME),^{1,3} the rates of good outcome were found to be 71% and 63%, respectively.³⁵ Therefore, these observations could explain the decrease in good outcomes over time reported in our study in which both early- and late-treated patients were selected with advanced imaging. Additionally, these findings seem to indicate that time remains a key variable in predicting clinical outcome on a population basis, but not at individual level, where it is just one of the many variables affecting outcome, reinforcing the view that a selection of patients only based on time is no longer justified.³⁶

Taken together, the data obtained in the present study suggest the possibility to extend the time window for EVT beyond 6 hours after onset in the real world using a combined approach based on the concomitant visual assessment of CTA collateral extent and CTP mismatch even in those centers not equipped with automated software programs able to calculate the different parameters of target mismatch. Nevertheless, the lack of a control group of untreated patients limits the strength of these findings since it precludes an actual assessment of treatment effect, the comparison with previous RCTs and as a consequence, the generalization of our results.

This study has other limitations, most of which are inherent to its observational nature. First, despite central monitoring of data quality and completeness, it is not possible to exclude reporting biases in a multicenter prospective national registry with self-reported clinical and outcome data. Second, the visual, qualitative interpretation of radiological findings could represent another drawback of the current analysis, since it is now widely accepted that threshold-based quantitative parameters obtained with automated software programs represent the best method for correctly identifying patients with AIS who can benefit from EVT beyond 6 hours after onset.^{9,10,12} However, our study showed a safety profile similar to that reported in the setting of clinical trials.^{9,10} Although RCTs remain the gold standard in the assessment of intended effects of interventions, observational studies can be useful for providing important information under everyday circumstances.

References

1. Campbell BC, Mitchell PJ, Kleinig TJ, Dewey HM, Churilov L, Yassi N, Yan B, Dowling RJ, Parsons MW, Oxley TJ, et al; EXTEND-IA Investigators. Endovascular therapy for ischemic stroke with perfusion-imaging selection. *N Engl J Med*. 2015;372:1009–1018. doi: 10.1056/NEJMoa1414792
2. Goyal M, Demchuk AM, Menon BK, Eesa M, Rempel JL, Thornton J, Roy D, Jovin TG, Willinsky RA, Sapkota BL, et al; ESCAPE Trial Investigators. Randomized assessment of rapid endovascular treatment of ischemic stroke. *N Engl J Med*. 2015;372:1019–1030. doi: 10.1056/NEJMoa1414905
3. Saver JL, Goyal M, Bonafe A, Diener HC, Levy EI, Pereira VM, Albers GW, Cognard C, Cohen DJ, Hacke W, et al; SWIFT PRIME Investigators. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke. *N Engl J Med*. 2015;372:2285–2295. doi: 10.1056/NEJMoa1415061
4. Berkhemer OA, Fransen PS, Beumer D, van den Berg LA, Lingsma HF, Yoo AJ, Schonewille WJ, Vos JA, Nederkoorn PJ, Wermer MJH, et al; MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke. *N Engl J Med*. 2015;372:11–20. doi: 10.1056/NEJMoa1411587
5. Jovin TG, Chamorro A, Cobo E, de Miquel MA, Molina CA, Rovira A, Román LS, Serena J, Abilleira S, Ribó M, et al; REVASCAT Trial Investigators. Thrombectomy within 8 hours after symptom onset in ischemic stroke. *N Engl J Med*. 2015;372:2296–2306. doi: 10.1056/NEJMoa1503780
6. Bracard S, Ducrocq X, Mas JL, Soudant M, Oppenheim C, Moulin T, Guillemin F; THRACE investigators. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke (THRACE): a randomised controlled trial. *Lancet Neurol*. 2016;15:1138–1147. doi: 10.1016/S1474-4422(16)30177-6
7. Goyal M, Menon BK, van Zwam WH, Dippel DW, Mitchell PJ, Demchuk AM, Dávalos A, Majoie CBLM, van der Lugt A, de Miquel MA, et al; HERMES collaborators. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. *Lancet*. 2016;387:1723–1731. doi: 10.1016/S0140-6736(16)00163-X
8. Saver JL, Goyal M, van der Lugt A, Menon BK, Majoie CB, Dippel DW, Campbell BC, Nogueira RG, Demchuk AM, Tomasello A, et al; HERMES Collaborators. Time to treatment with endovascular thrombectomy and outcomes from ischemic stroke: a meta-analysis. *JAMA*. 2016;316:1279–1288. doi: 10.1001/jama.2016.13647
9. Albers GW, Marks MP, Kemp S, Christensen S, Tsai JP, Ortega-Gutierrez S, McTaggart RA, Torbey MT, Kim-Tenser M, Leslie-Mazwi T, et al; DEFUSE 3 Investigators. Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging. *N Engl J Med*. 2018;378:708–718. doi: 10.1056/NEJMoa1713973
10. Nogueira RG, Jadhav AP, Haussen DC, Bonafe A, Budzik RF, Bhuva P, Yavagal DR, Ribo M, Cognard C, Hanel RA, et al; DAWN Trial Investigators. Thrombectomy 6 to 24 hours after

stroke with a mismatch between deficit and infarct. *N Engl J Med.* 2018;378:11–21. doi: 10.1056/NEJMoa1706442

11. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, Biller J, Brown M, Demaerschalk BM, Hoh B, et al; American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke.* 2018;49:e46–e110. doi: 10.1161/STR.000000000000158

12. Turc G, Bhogal P, Fischer U, Khatri P, Lobotesis K, Mazighi M, Schellinger PD, Toni D, de Vries J, White P, et al. European Stroke Organisation (ESO)- European Society for Minimally Invasive Neurological Therapy (ESMINT) guidelines on mechanical thrombectomy in acute ischemic stroke. *J Neurointerv Surg.* 2019;11:535–538. doi: 10.1136/neurintsurg-2018-014568

13. Mangiafico S, Pracucci G, Saia V, Nencini P, Inzitari D, Nappini S, Vallone S, Zini A, Fuschi M, Cerone D, et al. The Italian Registry of Endovascular Treatment in Acute Stroke: rationale, design and baseline features of patients. *Neurol Sci.* 2015;36:985–993. doi: 10.1007/s10072-014-2053-5

14. Casetta I, Pracucci G, Saletti A, Saia V, Padroni M, De Vito A, Inzitari D, Zini A, Vallone S, Bergui M, et al; The Italian Registry of Endovascular Treatment in Acute Stroke. Combined intravenous and endovascular treatment versus primary mechanical thrombectomy. The Italian Registry of Endovascular Treatment in Acute Stroke. *Int J Stroke.* 2019;14:898–907. doi: 10.1177/1747493019851279

15. SPREAD (Stroke Prevention and Educational Awareness Diffusion). Italian Guidelines For Stroke Prevention And Management. 8th ed. <http://iso-spread.it>. Accessed January 5, 2020.

16. Tan IY, Demchuk AM, Hopyan J, Zhang L, Gladstone D, Wong K, Martin M, Symons SP, Fox AJ, Aviv RI. CT angiography clot burden score and collateral score: correlation with clinical and radiologic outcomes in acute middle cerebral artery infarct. *AJNR Am J Neuroradiol.* 2009;30:525–531. doi: 10.3174/ajnr.A1408

17. Menon BK, d’Esterre CD, Qazi EM, Almekhlafi M, Hahn L, Demchuk AM, Goyal M. Multiphase CT angiography: a new tool for the imaging triage of patients with acute ischemic stroke. *Radiology.* 2015;275:510–520. doi: 10.1148/radiol.15142256

18. Wintermark M, Flanders AE, Velthuis B, Meuli R, van Leeuwen M, Goldsher D, Pineda C, Serena J, van der Schaaf I, Waaijjer A, et al. Perfusion-CT assessment of infarct core and penumbra: receiver operating characteristic curve analysis in 130 patients suspected of acute hemispheric stroke. *Stroke.* 2006;37:979–985. doi: 10.1161/01.STR.0000209238.61459.39

19. Turk A, Magarik JA, Chaudry I, Turner RD, Nicholas J, Holmstedt CA, Chalela J, Hays A, Lazaridis C, Jauch E, et al. CT perfusion-guided patient selection for endovascular treatment of acute ischemic stroke is safe and effective. *J Neurointerv Surg.* 2012;4:261–265. doi: 10.1136/neurintsurg-2011-010067

20. Higashida RT, Furlan AJ, Roberts H, Tomsick T, Connors B, Barr J, Dillon W, Warach S, Broderick J, Tilley B, et al; Technology Assessment Committee of the American Society of Interventional and Therapeutic Neuroradiology; Technology Assessment Committee of the

Society of Interventional Radiology. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. *Stroke*. 2003;34:e109–e137. doi: 10.1161/01.STR.0000082721.62796.09

21. Hacke W, Kaste M, Fieschi C, von Kummer R, Davalos A, Meier D, Larrue V, Bluhmki E, Davis S, Donnan G, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. *Lancet*. 1998;352:1245–1251. doi: 10.1016/s0140-6736(98)08020-9

22.

Vagal A, Menon BK, Foster LD, Livorine A, Yeatts SD, Qazi E, d'Esterre C, Shi J, Demchuk AM, Hill MD, et al. Association between CT angiogram collaterals and CT perfusion in the interventional management of stroke III trial. *Stroke*. 2016;47:535–538. doi: 10.1161/STROKEAHA.115.011461

23.

Bivard A, Levi C, Lin L, Cheng X, Aviv R, Spratt NJ, Lou M, Kleinig T, O'Brien B, Butcher K, et al. Validating a predictive model of acute advanced imaging biomarkers in ischemic stroke. *Stroke*. 2017;48:645–650. doi: 10.1161/STROKEAHA.116.015143

24. Natarajan SK, Snyder KV, Siddiqui AH, Ionita CC, Hopkins LN, Levy EI. Safety and effectiveness of endovascular therapy after 8 hours of acute ischemic stroke onset and wake-up strokes. *Stroke*. 2009;40:3269–3274. doi: 10.1161/STROKEAHA.109.555102

25. Abou-Chebl A. Endovascular treatment of acute ischemic stroke may be safely performed with no time window limit in appropriately selected patients. *Stroke*. 2010;41:1996–2000. doi: 10.1161/STROKEAHA.110.578997

26. Jovin TG, Liebeskind DS, Gupta R, Rymer M, Rai A, Zaidat OO, Abou-Chebl A, Baxter B, Levy EI, Barreto A, et al. Imaging-based endovascular therapy for acute ischemic stroke due to proximal intracranial anterior circulation occlusion treated beyond 8 hours from time last seen well: retrospective multicenter analysis of 237 consecutive patients. *Stroke*. 2011;42:2206–2211. doi: 10.1161/STROKEAHA.110.604223

27. Jung S, Gralla J, Fischer U, Mono ML, Weck A, Lüdi R, Heldner MR, Findling O, El-Koussy M, Brekenfeld C, et al. Safety of endovascular treatment beyond the 6-h time window in 205 patients. *Eur J Neurol*. 2013;20:865–871. doi: 10.1111/ene.12069

28. Abilleira S, Cardona P, Ribó M, Millán M, Obach V, Roquer J, Cánovas D, Martí-Fàbregas J, Rubio F, Alvarez-Sabín J, et al; Catalan Stroke Code and Reperfusion Consortium. Outcomes of a contemporary cohort of 536 consecutive patients with acute ischemic stroke treated with endovascular therapy. *Stroke*. 2014;45:1046–1052. doi: 10.1161/STROKEAHA.113.003489

29. Gratz PP, Jung S, Schroth G, Gralla J, Mordasini P, Hsieh K, Heldner MR, Mattle HP, Mono ML, Fischer U, et al. Outcome of standard and high-risk patients with acute anterior circulation stroke after stent retriever thrombectomy. *Stroke*. 2014;45:152–158. doi: 10.1161/STROKEAHA.113.002591

30. Aghaebrahim A, Leiva-Salinas C, Jadhav AP, Jankowitz B, Zaidi S, Jumaa M, Urrea X, Amorim E, Zhu G, Giurgiutiu D-V, et al. Outcomes after endovascular treatment for anterior circulation stroke presenting as wake-up strokes are not different than those with witnessed onset beyond 8 hours. *J Neurointerv Surg*. 2015;7:875–880. doi: 10.1136/neurintsurg-2014-011316
31. Tsurukiri J, Ota T, Jimbo H, Okumura E, Shigeta K, Amano T, Ueda M, Matsumaru Y, Shiokawa Y, Hirano T. Thrombectomy for stroke at 6-24 hours without perfusion CT software for patient selection. *J Stroke Cerebrovasc Dis*. 2019;28:774–781. doi: 10.1016/j.jstrokecerebrovasdis.2018.11.022
32. Mokin M, Abou-Chebl A, Castonguay AC, Nogueira RG, English JD, Farid H, Gupta R, Martin C, Holloway WE, Haussen DC, et al; NASA and TRACK investigators. Real-world stent retriever thrombectomy for acute ischemic stroke beyond 6 hours of onset: analysis of the NASA and TRACK registries. *J Neurointerv Surg*. 2019;11:334–337. doi: 10.1136/neurintsurg-2018-014272
33. Alsahli K, Cheung AK, Wijesuriya N, Cordato D, Zagami AS, Wenderoth JD, Chiu AH, Tay K, Cappelen-Smith C. Thrombectomy in stroke of unknown onset, wake up stroke and late presentations: Australian experience from 2 comprehensive stroke centres. *J Clin Neurosci*. 2019;59:136–140. doi: 10.1016/j.jocn.2018.10.114
34. Jadhav AP, Desai SM, Kenmuir CL, Rocha M, Starr MT, Molyneaux BJ, Gross BA, Jankowitz BT, Jovin TG. Eligibility for endovascular trial enrollment in the 6- to 24-hour time window: analysis of a single comprehensive stroke center. *Stroke*. 2018;49:1015–1017. doi: 10.1161/STROKEAHA.117.020273
35. Albers GW. Late window paradox. *Stroke*. 2018;49:768–771. doi: 10.1161/STROKEAHA.117.020200
36. von Kummer R. Treatment of ischemic stroke beyond 3 hours: is time really brain? *Neuroradiology*. 2019;61:115–117. doi: 10.1007/s00234-018-2122-1

Table 1. Clinico-Demographic Characteristics, and Outcome of Patients Treated Within and Beyond 6 Hours

	Beyond 6 Hours	Within 6 Hours
Sex, men, n (%)	163 (49.8)	1352 (49.5)
Age, mean±SD	66.8±14.9*	69.73±13.7*
History, n/N (%)		
Hypertension	186/319 (58.3)	1625/2585 (62.9)
Diabetes mellitus	51/317 (16.1)	408/2585 (15.8)
Dyslipidemia	67/317 (21.1)	641/2585 (24.8)
Atrial fibrillation	92/318 (28.9)	878/2584 (34.0)
TIA/stroke (last 3 mo)	12/327 (3.6)	117/2720 (4.3)
Smokers	67/317 (21.1)	636/2585 (24.6)
History of malignancy	16/320 (5.0)	155/2725 (5.7)
Baseline NIHSS (median, IQR)	16, 12–20†	18, 13–21†
ASPECTS (median, IQR)	8, 7–10‡	9, 8–10‡
IV thrombolysis, n/N (%)	25/327 (27.6)§	1774/2730 (65.0)§
Onset to groin puncture time (median, IQR)	430 (390–570)*	220 (170–273)*
Site of occlusion n (%)	Total number 327‡	Total number 2730‡
Middle cerebral artery, proximal (M1)	147 (45.0)	1338 (49.0)
Middle cerebral artery, distal (M2)	43 (13.1)	421 (15.4)
Carotid T	52 (15.9)	446 (16.3)
Tandem occlusion	85 (26.0)†	525 (12.9)†

ASPECTS indicates Alberta Stroke Program Early CT Score; IQR, interquartile range; IVT, intravenous thrombolysis; NIHSS, National Institutes of Health Stroke Scale; and TIA, transient ischemic attack.

*

P<0.001,

†

P<0.01,

‡

P<0.05,

§

P<0.0001.

Table 2. Outcome and Safety Data

	Beyond 6 Hours (n=327)	Within 6 Hours (n=2730)	AdjOR (95% CI)
Shift analysis			1.57 (1.25–1.98)
Outcomes, n (%)			
mRS 0–1	88 (26.9)	908 (33.3)	0.52 (0.38–0.7)
mRS 0–2	135 (41.3)	1271 (46.6)	0.58 (0.43–0.77)
mRS 0–3	174 (53.2)	1617 (59.2)	0.59 (0.44–0.78)
Death	56 (17.1)	443 (16.2)	1.19 (0.8–1.7)
TICI 2b/3	232 (70.9)	1999 (73.2)	0.7 (0.6–1.01)
TICI 3	167 (51.1)	1505 (5.1)	0.78 (0.6–1.003)
sICH	22 (6.7)	189 (6.9)	0.97 (0.58–1.6)

Data on final recanalization were not available for 3 patients treated beyond 6 hours. AdjOR indicates odds ratio adjusted for age, sex, site of occlusion, baseline, stroke severity, atrial fibrillation, hypertension, diabetes mellitus, dyslipidemia, smoke; mRS, modified Rankin Scale; sICH, symptomatic intracranial hemorrhage; and TICI, Thrombolysis in Cerebral Infarction.

Outcomes by final TICI score are reported in Table 3.

Table 3. Outcome and Safety Data of Patients Treated Beyond 6 Hours According to Final TICI Score

	TICI 0	TICI 1	TICI 2a	TICI 2b	TICI 3
No. of patients	27	22	43	65	167
Outcome n (%)					
Death	11 (40.7)	8 (36.4)	5 (11.6)	10 (15.4)	20 (12)
sICH	0	2 (9.1)	3 (7)	6 (9.2)	10 (6)
3-month mRS					
mRS 0–1	1 (3.7)	2 (9.1)	7 (16.3)	18 (27.7)	60 (35.9)
mRS 0–2	3 (11.1)	3 (13.6)	19 (44.2)	22 (33.8)	88 (52.7)
mRS 0–3	6 (22.2)	6 (27.3)	26 (6.5)	30 (46.2)	106 (63.5)

Table 4. Demographic, Baseline Clinical Characteristics, Site of Occlusion, Interventional Workflow, and Outcome of Patients Treated Beyond 6 Hours, According to Onset to Groin Puncture Time

	6–12 Hours (n=278)	12–24 Hours (n=49)	AdjOR (95%CI)
Sex, men n (%)	135 (48.6)	28 (57.1)	
Age (mean±SD)	66.7 (15.2)	67.2 (13.1)	
History, n/N %			
Hypertension	159/273 (58.2)	27/46 (58.7)	
Diabetes mellitus	47/270 (17.4)	4/47 (8.5)	
Dyslipidemia	55/270 (20.4)	12/47 (25.4)	
Atrial fibrillation	82/271 (30.2)	10/47 (21.2)	
Smoker	56/270 (20.7)	11/47 (22.2)	
Median (IQR) baseline NIHSS	16 (12–20)	15.5 (10–22.75)	
Site of occlusion, n (%)			
M1	131 (47.1)	16 (32.7)	
M2	37 (13.3)	6 (12.2)	
Carotid T occlusion	43 (15.5)	9 (18.4)	
Tandem occlusion	67 (24.1)	18 (36.7)	
Median (IQR) time to groin puncture	420 (386.5–494)*	953 (826–1130)*	
Outcome, n (%)			
mRS 0–1	78 (28.1)	10 (20.4)	2 (0.8–4.9)
mRS 0–2	118 (42.4)	17 (34.7)	2 (0.9–4.3)
mRS 0–3	154 (55.4)	20 (40.8)	2.6 (1.2–5.5)
Death	47 (16.9)	9 (18.4)	1.04 (0.4–2.7)
TICI 2b/3	198 (71.2)	34 (69.4)	0.9 (0.4–1.9)
TICI 3	144 (51.8)	23 (46.9)	1.1 (0.5–2.2)
sICH	17 (6.1)	5 (10.2)	0.5 (0.2–1.8)

Table 5. Overview of Observational Studies on EVT Beyond 6 Hours

	No. of Patients	Age*	Baseline NIHSS†	mRS 0–2‡	Death‡	siCH
Natarajan et al ²⁴	30	72 (range 24–91)	12 (range, 5–22)	33.3	20	10
Abou-Chebl ²⁵	21	59.4 (17.2)	17.8 (5.5) mean (SD)	43	23.8 (30-day)	9.5
Jovin ²⁶	169	64 (16)	17 (range 10–29)	40	25	10
Jung ²⁷	128	61.1 (15.1)	15 (range 2–36)	35.2	26.2	3.7
Turk, 2013 ¹⁷	70	64.9	15.1	45.5	21.2	5.6
Abilleira et al ²⁸	154	65 (14.2)	17 (13–21)	35.7	23.4	8.4
Gratz ²⁹	22	67.1 (14.5)	16.5 (range 8–22)	36.4	18.2	9.1
Aghaebrahim et al ³⁰	128	64 (13.6)	14 (5.4) mean (SD)	50	22	5.5§
Tsurukiri et al ³¹	31	74 (9)	17 (13–20)	32	13	10
Mokin et al ³²	248	66.1 (14.6)	16 (13–20)	46.2	21.6	11
		69.9 (14)	16 (12–20)			
Alsahli et al ³³	56	72 (60–82)	15 (8–20)	62	14	7
Present study	327	66.8 (14.9)	16 (12–20)	41.3	17.1	6.7